Inmunomodulación por pentoxifilina: ¿realidad o fantasía?

Actas Dermo-Sifiliograficas

Volumn 88, Issue 7-8, 1997, Pages 373-384

  Pizarro, Ángel ^c,d   Robayna, Goretti ^c   Rubio, Francisco A ^c   García Tobaruela, Almudena ^a   Muñoz Fernández, M Ángeles ^b  

^a Servicios Dermatologia Med Interna

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d Urb Parque Real 2 401 ^*  (Spain)

Author keywords

Antiinflammatory therapy; Cytokines; Immune modulation; Pentoxifylline

Indexed keywords

PENTOXIFYLLINE;

ANTIINFLAMMATORY ACTIVITY; DRUG EFFECT; DRUG EFFICACY; ERYTHROCYTE DEFORMABILITY; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LEUKOCYTE ACTIVATION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0030761828     PISSN: 00017310     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (164)

1. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
2. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994;45:339-45.
3. Stergachis A, Sheingold S, Luce BR, Psaty BM, Revicki DA. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med 1992;152:1220-4.
4. Aviado DM, Dettelbach HR. Pharmacology of pentoxifylline. A hemorheological agent for the treatment of intermittent claudication. Angiology 1984;35:407-17.
5. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994;30:603-21.
6. Ely H. Pentoxifylline therapy in dermatology. A review of localized hyperviscosity and its effects on the skin. Dermatol Clin 1988;6:585-608.
7. Ely H. White blood cells as mediators of hyperviscosity- induced tissue damage in neutrophilic vascular reactions: Therapy with pentoxifylline. J Am Acad Dermatol 1989;20: 677-80.
8. Schröer RH. Antithrombotic potential of pentoxifylline, a hemorheologically active drug. Angiology 1985;36:387-98.
9. Ambrus JL, Stadler S, Kulaylar M. Hemorrheologic effects of metabolites of pentoxifylline (Trental). J Med 1995;26:65-75.
10. Sonkin PL, Kelly LW, Sinclar SH, Hatchell DL. Pentoxifylline increases retinal capillary blood flow velocity in patients with diabetes. Arch Ophtalmol 1993;111:1647-52.
11. Phillips TJ, Dover JS, Leg ulcers. J Am Acad Dermatol 1991;25:965-87.
12. Song CW, Makepeace CM, Griffin RJ et al. Increase in tumor blood flow by pentoxifylline. Int J Radiat Oncol Biol Phys 1994;29:433-7.
13. Mandell GL. ARDS, neutrophils, and pentoxifylline. Am Rev Respir Dis 1988;138:1103-5.
14. Zabel P, Schade FU, Schlaak M. Inhibition of endogenous TNF formation by pentoxifylline. Immunobiology 1993;187: 447-63.
15. Anaya JM, Espinoza LR. Phosphodiesterase inhibitor pentoxifylline:an antiinflammatory/immunomodulatory drug potentially useful in some rheumatic diseases. J Rheumatol 1995;22:595-9.
16. Dezube BJ. Pentoxifylline for the treatment of infection with human immunodeficiency virus. Clin Infect Dis 1994;18: 285-7.
17. Pizarro A Pentoxifilina:nuevas propiedades y aplicaciones terapéuticas. Piel 1993;8:52-5.
18. Ely H. Is pentoxifylline the drug of the decade? J Am Acad Dermatol 1994;30:39-42.
19. Hill HR, Augustine NH, Newton JA, Shigeoka AO, Morris E, Sacchi F. Correction of a developmental defect in neu- trophil activation and movement. Am J Pathol 1987;128: 307-14.
20. Salver JL, Bohnsack JF, Knape WA, Shigeoka AO, Ashwood ER, Hill HR. Mechanisms of tumor necrosis factor-a alteration of PMN adhesion and migration. Am J Pathol 1990;136:831-41.
21. Zheng H, Crowley JJ, Chan JC et al. Attenuation of tumor necrosis factor-induced endothelial cell cytotoxicity and neutrophil chemiluminiscence. Am Rev Respir Dis 1990;142: 1073-8.
22. Roberts PJ, Yong KL, Khwaja A et al. Pentoxifylline at clinically achievable levels inhibits FMLP-induced neutrophil respenses, but not priming, upregulation of cell-adhesion molecules, or migration induced by GM-CSF. Eur J Haematol 1993;50:1-10.
23. Buescher ES, McIlheran SM, Banks SM, Vadhan-Raj S. Alteration of the functional effects of granulocyte-macrophage colony-stimulating factor on polymorphonuclear leukocytes by membrane-fluidizing agents. Infect Immun 1990;58: 3002-8.
24. Hammerschmidt DE, Kotasek D, McCarthy T, Huh PW, Freyburger G, Vercelotti GM. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988;112:254- 63.
25. Sullivan GV, Carper HT, Novick VJ, Mandell GM. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline. Infect Immun 1988;56:1722-9.
26. Beermann B, Ings R, Mansby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther 1985;37:25-8.
27. Bianco JA, Appelbaum FR, Nemunaitis J et al. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991;78:1205-11.
28. López-Jiménez J, Cancelas JA, Valino JM et al. Effects of oral pentoxifylline on TNF-alpha levels, transplant-related toxicities and engraftment after bone marrow transplantation. Bone Marrow Transplant 1994;14:1011-3.
29. DeVault GA, Kohan DE, Nelson EW, Holman JR. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3. Transplantation 1994;57: 532-40.
30. Martich GD, Danner RL, Ceska M, Suffredini AF. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med 1991;173:1021-4.
31. Maksymowych WP, Avina-Zubieta A, Luong MH, Russell AS. An open study of pentoxifylline in the treatment of severe refractory rheumatoid arthritis. J Rheumatol 1995;22:625- 9.
32. Rames A, Poirier JM, LeCoz F et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther 1990;47: 354-9.
33. Beelen DW, Sayer HG, Franke M et al. Constant intravenous pentoxifylline infusions in allogenic marrow transplant recipients: results of a dose escalation study. Bone Marrow Transplant 1993;12:363-70.
34. Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 1994;24:648-54.
35. Vmcenti F, Danovitch GM, Neylan JF, Steiner RS, Everson MP, Gaston RS. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3. A randomized, double-blind placebo-controlled study. Transplantation 1996;61:573-7.
36. Shapiro CL, Dezube BJ, Tretyakov O et al. Dose escalation of N,N'N"-triethylenethiophosphoramide combined with pentoxifylline for advanced breast cancer. Clin Cancer Res 1995;1:791-6.
37. Mole L, Margolis D, Ghotbi L, Holodniy M. The use of pentoxifylline alone in HIV-infected patients. J Acquired Immune Defic Syndr 1994;7:519-21.
38. Bianco JA, Singer JW. Pentoxifylline did not prevent transplant-related toxicity in 31 consecutive allogeneic bone marrow transplant, recipients. Response. Blood 1992;80: 2683-4.
39. Zeni F, Pain P, Vindimian M et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: Results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996;24:207-14.
40. Thompson JA, Bianco JA, Benuynes MC et al. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and lymphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res 1994;54: 3436-41.
41. Wahba-Yahav AV. Intractable chronic furunculosis: prevention of recurrences with pentoxifylline. Acta Derm Venereol (Stockh) 1992;72:461-2.
42. Wahba-Yahav AV. Pentoxifylline in intractable recurrent aphthous stomatitis: An open trial. J Am Acad Dermatol 1995;33:680-2.
43. Crouch SPM, Fletcher J. Effect of ingested pentoxifylline on neutrophil superoxide anion production. Infect Immun 1992;60:4504-9.
44. Welsh CH, Lien D, Worthen GS, Weil JV. Pentoxifylline decreases endotoxin-induced pulmonary neutrophil sequestration and extravascular protein accumulation in the dog. Am Rev Respir Dis 1988;138:1106-14.
45. Harada H, Ishizaka A, Yonemura M et al. The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 1989;140: 974-80.
46. Okabayashi K, Aoe M, DeMeester SR, Cooper JD, Patterson GA. Pentoxifylline reduces lung allograft reperfusion injury. Ann Thorac Surg 1994;58:50-6.
47. Chapelier A, Reignier J, Mazmanian M et al. Amelioration of reperfusion injury by pentoxifylline after lung transplantation. J Heart Lung Transplant 1995;14:676-83.
48. Stricter RM, Remick DG, Ward PA et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifyllme. Biochem Biophys Res Commun 1988;155: 1230-6.
49. Han J, Thomson P, Beutler B. Dexamethasone and pentoxifyline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990;172:391-4.
50. Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991;110:192-8.
51. Schandené L, Vandenbussche P, Crusiaux A et al. Differential effects of pentoxifylline on the production of tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) by monocytes and T cells. Immunology 1992;76: 30-4.
52. Neuner P, Klosner C, Schauer E et al. Pentoxifylline in vivo down-regulates the release of IL-1β, IL-6, IL-8 and tumour necrosis factor-α by human peripheral blood mononuclear cells. Immunology 1994;83:262-7.
53. Singer JW, Bianco JA, Takahashi G, Simrell C, Petersen J, Andrews DF. Effect of methylxanthine derivatives on T cell activation. Bone Marrow Transplant 1992;10:19-25.
54. Tilg H, Eibl B, Pichl M et al. Immune response modulation by pentoxifylline in vitro. Transplantation 1993;56:196-201.
55. Rieneck K, Diamant M, Haahr PM, Schönharting M, Bendtzen K. In vitro immunomodulatory effects of pentoxifylline. Immunol Lett 1993;37:131-8.
56. Semmler J, Gebert U, Eisenhut T et al. Xanthine derivatives: comparison between suppression of tumour necrosis factor-α production and inhibition of cAMP phosphodiesterase activity. Immunology 1993;78:520-5.
57. Endres S, Fülle HJ, Sinha B et al. Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-α and interleukin-1β by human mononuclear cells. Immunology 1991;72:56-60.
58. Jewett A, Bonavida B. Pentoxifylline suppresses interleukin- 2-mediated activation of immature human natural killer cells by inhibiting endogenous tumor necrosis factor-alpha secretion. J Clin Immunol 1994;14:31-8.
59. Schmidt-Choudhury A, Furuta GT, Lavigne JA, Galli S, Wershil BK. The regulation of tumor necrosis factor-α production in murine mast cells: pentoxifylline or dexamethasone inhibits IgE-dependent production of TNF-a by distinct mechanisms. Cell Immunol 1996;171:140-6.
60. Tracey KJ, Cerami A. Tumor necrosis factor:A pleiotropic cytokine and therapeutic target. Annu Rev Med 1994;45: 491-503.
61. Rosenthal LA, Taub DD, Moors MA, Blank KJ. Methyxanthine-induced inhibition of the antigen- and superantigen- specific activation of T and B lymphocytes. Immunopharmacology 1992;24:203-17.
62. Schandené L, Gérard C, Crusiaux A, Abramowicz D, Velu T, Goldman M. Interleukin-10 inhibits OKT3-induced cytokine release: in vitro comparison with pentoxifylline. Transplant Proc 1993;25:55-6.
63. Thanhauser A, Reiling N, Böhle A et al. Pentoxifyllinc:a potent inhibitor of IL-γ and IFN-a biosynthesis and BCG- induced cytotoxicity. Immunology 1993;80:151-6.
64. Parhar RS, Ernst P, Sheth K, Einspenner M, Al-Sedairy S. Mechanism of pentoxifylline mediated down-regulation of killer lineage cell functions. Mediators Inflammation 1993;2:379-84.
65. Funk JO, Ernst M, Schönharting MM, Zabel P. Pentoxifylline and dexamethasone have partially synergistic immuno- modulatory effects in vitro. Arch Dermatol Res 1995;287: 400.
66. Van Furth AM, Steenwijk TM, Langermans JAM, van Furth R. In vitro effect of dexamethasone, pentoxifylline and anti-endotoxin monoclonal antibody on the release of proinflammatory mediators by human leukocytes stimulated with Haemophilus influenzae type B. Pediatr Res 1994;35:725-8.
67. Van Furth AM, Seijmonsbergen EM, Langermans JAM, van der Meide PH, van Furth R. Effect of xanthine derivatives and dexamethasone on Streptococcus pneumoniae-stimu lated production of tumor necrosis factor alpha, interleukin-1β (IL-1β), and IL-10 by human leukocytes. Clin Diagn Lab Immunol 1995;2:689-92.
68. Reimund JM, Dumont S, Muller Ch, Baumann R, Poindron P, Duclos B. Effect of pentoxifylline (POF) upon cytokine secretion by peripheral mononuclear cells (PBMNC) and intestinal biopsies in inflammatory bowell diseases. Gastroenterology 1995:108:A900.
69. Waage A, Sorensen M, Stordal B. Differential effect of oxpentifylline on tumour necrosis factor and interleukin-6 production. Lancet 1990;ii:543.
70. Bienvenu J, Coulon L, Barbier Yet al. Study of pentoxifylline induced modulation of TNFα and interleukin-6 secretion in healthy and septic patients by the use of an ex-vivo model on whole blood. Nouv Rev Fr Hematol 1992;34 (suppl):S65-S67.
71. Prada J, Prager C, Neifer S, Bienzle U, Kremsner PG. Production of interleukin-6 by human and murine mononuclear leukocytes stimulated with Plasmodium antigens is enhanced by pentoxifylline, and tumor necrosis factor secretion is reduced. Infect Immun 1993;61:2737-40.
72. Navarro J, Pizarro A, Fernández-Cruz E, Fresno M, Muñoz- Fernández MA. Pentoxifylline preferentially inhibits interleukin-10 production by HIV-1-infected human T cells. AIDS 1994;8:1192-94.
73. Platzer C, Meisel Ch, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-a and cAMP elevating drugs. Int Immunol 1995;7:517-23.
74. Khabar KSA, Dzimiri M, Parhar RS et al. Pentoxifylline (PTX) selectively potentiates cyclosporine (CsA)-mediated suppression of cell mediated lymphocytotoxicity. Transplantation 1996;61:838-41.
75. Bruynzeel I, van der Raaji LMH, Stoof TJ, Willemze R. Pentoxifylline inhibits T-cell adherence to keratinocytes. J Invest Dermatol 1995;104:1004-7.
76. Weiss JM, Vanscheidt W, Pilarski KA et al. Pentoxifylline inhibits tumor necrosis factor-a (TNF-α)-induced T-lymphoma cell adhesion to endothelioma cells. J Invest Dermatol 1995;104:824-8.
77. Dosquet C, Weill D, Wautier JL. Molecular mechanism of blood monocyte adhesion to vascular endothelial cells. Nouv Rev Fr Hematol 1992;34 (suppl):S55-S59.
78. Kovach NL, Lindgren CG, Fefer A, Thompson JA, Yednock T, Harlan JM. Pentoxifylline inhibits integrin-mediated adherence of interleukin-2-activated human peripheral blood lymphocytes to human umbilical vein endothelial cells, matrix components, and cultured tumor cells. Blood 1994;84:2234-42.
79. De Fraissinette A, Berman B, Duncan M, Lefevre L. Effects of pentoxifylline on interferon-gamma (IFN-γ) and tumour necrosis factor-alpha (TNF-α) induction of intercellular adhesion molecule-1 (ICAM-1) expression on human normal keratinocytes and Langerhans cells. Eur J Dermatol 1992;2:265-72.
80. Thompson JA, Lindgren CG, Benyunes MC, Bianco JA, Shields AF, Fefer A. The effects of pentoxifylline on the generation of human lymphokine-activated killer cell cytotoxicity. J Immunother 1993;13:84-90.
81. Reed WR, DeGowin RL. Suppressive effects of pentoxifylline on natural killer cell activity. J Lab Clin Med 1992;119:763-71.
82. Ollivier V, Ternisien C, Vu T, Hakim J, de Prost D. Pentoxifylline inhibits the expression of tissue factor mRNA in endotoxin-activated human monocytes. FEBS Lett 1993;322: 231-4.
83. Pradier O, Abramowicz D, Capel P, Goldman M. Procoagulant properties of OKT3 at the monocyte level:inhibition by pentoxifylline. Transplant Proc 1993;25 (suppl 1):39-40.
84. Sathe SS, Tsigler D, Sarai A, Kumar P. Pentoxifylline impairs macrophage defense against Mycobacterium avium complex. J Infect Dis 1995;172:863-6.
85. Fazely F, Dezube BJ, Allen-Ryan J, Pardee AB, Ruprecht RM. Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T cells. Blood 1991;77:1653-6.
86. Peterson PK, Gekker G, Chao CC et al. Human cytomegalovirus-stimulated peripheral blood mononuclear cells induce HIV-1 replication via a tumor necrosis factor-α- mediated mechanism. J Clin Invest 1992;89:574-80.
87. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-kB action. J Acquired Immune Defic Syndr 1993;6:778- 86.
88. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB. Cooperative inhibition of NF-kB and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci USA 1993;90:11044-8.
89. Angel JB, Saget BM, Walsh SP et al. Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. AIDS 1995;9:1137-44.
90. Navarro J, Punzón MC, Pizarro A, Fernández-Cruz E, Fresno M, Muñoz-Fernández MA. Pentoxifylline inhibits acute HIV-1 replication in human T cells by a mechanism not involving inhibition of tumour necrosis factor synthesis or nuclear factor-kB activation. AIDS 1996;10:469-75.
91. a ed. México: Editorial Médica Panamericana, 1991:605-23.
92. Cronstein BN. A novel approach to the development of anti-inflammatory agents: adenosine release at inflamed sites. J Invest Med 1995;43:50-7.
93. Saijadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-α expression by adenosine. Role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
94. Rao KMK, Crawford J, Currie MS, Cohen HJ. Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils. J Cell Physiol 1988;137:577-82.
95. Rao KMK, Currie MS, McCachren CSS, Cohen HJ. Pentoxifylline and other methyl xanthines inhibits interleukin-2 receptor expression in human lymphocytes. Cell Immunol 1991;135:314-25.
96. Polson JB, Strada SJ. Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol 1996;36:403-27.
97. Barnes PJ. Cyclic nucleotides and phosphodiesterases and airway function. Eur Respir J 1995;8:457-62.
98. Müller T, Engels P, Fozard JR. Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. Trends Pharmacol Sci 1996;17:294-8.
99. Moore AR, Willoughby DA. The role of cAMP regulation in controlling inflammation. Clin Exp Immunol 1995;101:387-9.
100. Netea MG, BloK WL, Kullberg BJ et al. Pharmacologic inhibitors of tumor necrosis factor production exert differential effects in lethal endotoxemia and in infection with live microorganisms in mice. J Infect Dis 1995;171:393-9.
101. Breuillé D, Farge MO, Rosé F, Arnal M, Attaix D, Obled O. Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. Am J Physiol (Endocrinol Metab) 1993;265:E660-E666.
102. Mah MP, Aeberhard EE, Gilliam MB, Sherman MP. Effects of pentoxifylline on in vivo leukocyte function and clearance of group B streptococci from preterm rabbit lungs. Crit Care Med 1993;21:712-20.
103. Van Leenen D, van der Poll T, Levi M et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993;151:2318-25.
104. Levi M, ten Cate H, Bauer KA et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994;93:114- 20.
105. Hadjiminas DJ, McMasters KM, Robertson SE, Cheadle WG. Enhanced survival from cecal ligation and puncture with pentoxifylline is associated with altered neutrophil trafficking and reduced interleukin-1β expression but not inhibition of tumor necrosis factor synthesis. Surgery 1994;116: 348-55.
106. Quezado ZMN Natanson C, Banks SM et al. Pentoxifylline increased tumor necrosis factor level and decreased survival in a canine model of Gram-negative septic shock. Clin Res 1993;41:252A.
107. Kremsner PG, Grundmann H, Neifer S et al. Pentoxifylline prevents murine cerebral malaria. J Infect Dis 1991;164:605-8.
108. Alegre ML, Gastaldello K, Abramowicz D et al. Evidence that pentoxifylline reduces anti-CD3 monoclonal antibody-induced cytokine release syndrome. Transplantation 1991;52:674-9.
109. Bemelmans MHA, Abramowicz D, Gouma DJ, Godman M, Buurman WA. In vivo T cell activation by anti-CD3 monoclonal antibody induces soluble TNF receptor release in mice. Effects of pentoxifylline, methylprednisolone, anti- TNF, and anti-IFN-g antibodies. J Immunol 1994;153:499- 506.
110. Anderson C, Stubbs S, Tubesing K, Elmets C. Evidence that TNF-α is a mediator of UVB-induced cutaneous photosensitivity. J Invest Dermatol 1995;104:600.
111. Oberyszyn TM, Ross MS, Long BW, Nill MR, Pellegrini AE, Robertson FM. Modulation of ultraviolet B induced epidermal and mesenchymal alterations by pentoxifylline. Proc Am Assoc Cancer Res 1995;36:125.
112. Edwards MJ, Abney DL, Miller FN. Pentoxifylline inhibits interleukin-2-induced leukocyte-endothelial adherence and reduces systemic toxicity. Surgery 1991;110:199-204.
113. Edwards MJ, Heniford BT, Klar EA, Doak KW, Miller FN. Pentoxifylline inhibits inteleukin-2 toxicity in C57BL/6 mice but preserves antitumor efficacy. J Clin Invest 1992;90:637-41.
114. Rott O, Cash E, Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur J Immunol 1993;23:1745-51.
115. Nataf S, Louboutin JP, Chabannes D, Fève JR, Muller JY. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol Scand 1993;88:97-9.
116. Kiely PD, Gillespie KM, Oliveira DBG. Oxpentifylline inhibits tumor necrosis factor-α mRNA transcription and protects against arthritis in mercuric chloride-treated Brown Norway rats. Eur J Immunol 1995;25:2899-2906.
117. Schwarz A, Krone C, Trautinger F et al. Pentoxifylline suppresses irritant and contact hypersensitivity reactions. J Invest Dermatol 1993;101:549-52.
118. Holzheimer RG, Molloy RG, O'Riordain DS et al. Long- term immunotherapeutic intervention with pentoxifylline in a mouse model of thermal injury and infection. J Trauma 1995;38:757-62.
119. Gilhar A, Grossman N, Kahanovicz S, Reuveni H, Cohen S, Eitan A. Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis. Acta Derm Venereol (Stockh) 1996;76:437-441.
120. Stadler I, Chadha KC, Nakeeb S et al. Pentoxifylline and meclofenamic acid treatment reduces clinical manifestations in a murine model of AIDS. J Pharmacol Exp Ther 1994;268:10-13.
121. Stanley SK, Sullivan M, Justement JS, Fauci AS. Effects of immunomodulatory drugs on HIV infection in the SCID- hu thymus. Clin Res 1994;42:156A.
122. Bennett WM, Elzinga LW, Porter GA, Rosen S. The effects of pentoxifylline on experimental chronic cyclosporine nephrotoxicity. Transplantation 1992;54:1118-20.
123. Carrier M, Perrault LP, Tronc F, Stewart DJ, Pelletier CL. Pentoxifylline decreases cyclosporine-induced renal endothelin release and vasoconstriction. Ann Thorac Surg 1993;55:490-2.
124. Ates E, Sharma P, Erkasap S et al. Cyclosporine nephrotoxicity in the ischemic kidney and the protective effect of pentoxifylline. A study in the rat. Transplantation 1996;62:864-7.
125. Pizarro A, Navarro A, Fonseca E, Vidaurrazaga C, Herranz P. Treatment of recurrent aphthous stomatitis with pentoxifylline. Br J Dermatol 1995;133:659-60.
126. Pizarro A, Herranz P, Navarro A, Casado M. Recurrent aphthous stomatitis: treatment with pentoxifylline. Acta Derm Venereol (Stockh) 1996;76:79-80.
127. Yasui K, Ohta K, Kobayashi M, Aizawa T, Komiyama A. Successful treatment of Behçet disease with pentoxifylline. Ann Intern Med 1996;124:891-3.
128. Huizinga TW, Dijkmans BAC, van der Velde EA et al. An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann Rheum Dis 1996;55:833-6.
129. Kam L, Casini-Raggi V, Cominelli F. Pentoxifylline: a novel treatment for ulcerative colitis. Gastroenterology 1995;108: A845.
130. Person JR. Dermatomyositis responding to pentoxifylline. Br J Dermatol 1995;134:593.
131. Omulecki A, Broniarczyk-Dyla G, Zak-Prelich M, Choczaj-Kukula A. Is pentoxifylline effective in the treatment of psoriasis? J Am Acad Dermatol 1996;34:714-5.
132. Schwarz T, Schwarz A, Krone C, Luger T. Pentoxifylline suppresses allergic patch test reactions in humans. Arch Dermatol 1993;129:513-4.
133. Balato N, Patruno C, Lembo G, Cuccurullo FM, Ayala F. Effect of pentoxifylline on patch test response. Contact Dermatitis 1996;34:153.
134. Bose SK. Pentoxifylline in the treatment of Parthenium dermatitis. J Eur Acad Dermatol Venereol 1996;7:284-6.
135. Calderó MJ, Landa N, Aguirre A, Díz-Péez L. Successful treatment of cutaneous PAN with pentoxifylline. Br J Dermatol 1993;128:706-7.
136. Nünberg W, Grabbe J, Czarnetzki BM. Urticarial vasculitis syndrome effectively treated with dapsone and pentoxifylline. Acta Derm Venereol (Stockh) 1995;75:54-6.
137. Soloeta R, Yanguas Y, González M, Goday J. Tratamiento del eritema anular centrífugo con pentoxifilina. Piel 1995;10:223.
138. Person JR. Angiolymphoid hyperplasia with eosinophilia may respond to pentoxifylline. J Am Acad Dermatol 1994;31:117-8.
139. Muhart M, Helfman T, Ferdel F. Successful use of intravenous steroids and pentoxifylline in the treatment of bullous hemorrhagic cellulitis. J Dermatol Treat 1996;7:193-4.
140. España A, Sánchez-Yus E, Serna MJ, Redondo P, Robledo A, Quintanilla M. Chronic balanius with palisading granuloma: an atypical genital localization of necrobiosis lipoidica responsive to pentoxifylline. Dermatology 1994;188:222-5.
141. Redondo P, Ruiz de Erenchun F, Iglesias ME, Monedero P, Quintanilla E. Toxic epidermal necrolysis. Treatment with pentoxifylline. Br J Dermatol 1994;130:688-9.
142. Dezube BJ, Fridovich-Keil JL, Bouvard I, Lange RF, Pardee AB. Pentoxifylline and wellbeing in patients with cancer. Lancet 1990;335:662.
143. Tuckey JA, Parry BR, McCall JL. Pentoxifylline and well- being in cancer. Lancet 1993;342:617.
144. Goldberg RM, Laprinzi CL, Mailliard JA et al. Pentoxifylline for the treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-9.
145. Anderson JA, Woodcock TM, Harry JI, Knott AW, Edwards MJ. The effects of oral pentoxifylline on interleukin-2 toxicity in patients with metastatic renal cell carcinoma. Eur J Cancer 1995;31A:714-7.
146. Carrier M, Pelletier GB, White M, Bois D, Pelletier LC. Effect of pentoxifylline on renal toxicity of cyclosporine: preliminary results. Transplant Proc 1994;26:2745-6.
147. Königsrainer A, Aichberger C, Riedman B, Steurer W, Ofner D, Margreiter R. Pentoxifylline as an adjunct to cyclosporine-based immunosuppression does not improve the outcome of renal transplantation. Transplant Proc 1995;27:1062-3.
148. Zabel P, Wolter DT, Schönharting MM, Schade UF. Oxpentifylline in endotoxaemia. Lancet 1989;ii:1474-7.
149. Lauterbach R, Zembala M. Pentoxifylline reduces plasma tumour necrosis factor-alpha concentration in premature infants with sepsis. Eur J Pediatr 1996;155:404-9.
150. Dezube BJ, Sherman ML, Fridovich-Keil JL, Allen-Ryan J, Pardee AB. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients:a pilot study. Cancer Immunol Immunother 1993;36:57-60.
151. Lissoni P, Ardizzola A, Perego MS et al. Inhibition of tumor necrosis factor-alpha secretion by pentoxifylline in advanced cancer patients with abnormally high blood levels of tumor necrosis factor-alpha. J Biol Regul Homeost Agents 1993;7:73-5.
152. Ardizzoia A, Lissoni P, Tancini G et al. Respiratory distress syndrome in patients with advanced cancer treated with pentoxifylline:a randomized study. Support Care Cancer 1993;1:331-3.
153. Shertty V, Gregory S, Gezer S et al. Effect of pentoxifylline and ciprofloxacin (cipro) on the levels of tumor necrosis factor alpha (TNF-α) in myelodisplastic syndromes (MDS). Blood 1995;86 (suppl 1):801a.
154. Graninger W, Thalhammer F, Locker G. Pentoxifylline in cerebral malaria. J Infect Dis 1991;164:829.
155. Di Perri G, Di Perri TG, Monteiro GB et al. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J Infect Dis 1995;171:1317-22.
156. Bauditz J, Rückert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet 1995;345:1445.
157. Dezube BJ, Lederman MM, Spritzler JG et al. High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. J Infect Dis 1995;171:1628-32.
158. Wallis RS, Nsubuga P, Whalen C et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996;174:727-33.
159. Remick DG, Negussie Y, Fekade D, Griffin G. Pentoxifylline fails to prevent the Jarisch-Herxheimer reaction or associated cytokine release. J Infect Dis 1996;174:627-30.
160. Neuner P, Klosner G, Schauer E et al. In vivo effects of pentoxifylline on ICAM-1 expression and TNF-α production by peripheral blood mononuclear cells. J Invest Dermatol 1993;100:574.
161. Boldt J, Müller M, Heesen M, Neuman K, Hempelmann GG. Influence of different volume therapies and pentoxifylline infusion on circulating soluble adhesion molecules in critically ill patients. Crit Care Med 1996;24:385-91.
162. Natanson C, Hoffman W, Suffredini AF, Eichacker PQ, Danner RL. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994;120:771-83.
163. Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 1996;334:1697-1702.
164. Boldt J, Müller M, Heyn S, Welters I, Hempelmann G. Influence of long-term continuous intravenous administration of pentoxifylline on endothelial-related coagulation in critically ill patients. Crit Care Med 1996;24:940-6.